Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2330 articles with Johnson & Johnson Family of Companies
-
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.
-
The U.S. Food and Drug Administration approved Janssen Pharmaceuticals’ Darzalex Faspro for adults with newly diagnosed light chain amyloidosis.
-
Clinical Catch-Up: January 11-15
1/18/2021
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news. -
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
-
Top 2020 Biopharma M&A Deals
1/6/2021
BioSpace highlights a number of the key M&A deals struck over the past 12 months. -
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
Vir and GSK Dose First Patient in COVID-19 Monoclonal Antibody Study and Other Pandemic Updates
12/18/2020
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19. -
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
-
Johnson & Johnson Names Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General to its Board of Directors - Dec 03, 2020
12/3/2020
Johnson & Johnson announced that Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General has been appointed to its Board of Directors.
-
As if attempting to steal hard-won research wasn’t bad enough, hackers are now hitting people where it really hurts – with e-documents containing malicious code embedded in false offers of employment.
-
Thankful for Biopharma Breakthroughs
11/26/2020
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year. -
Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Awardees of the Seoul Innovation QuickFire Challenge on Healthcare for the New Normal in Collaboration with the SMG and Korea Health Industry Development Institute
11/24/2020
Awardees DC Medical and deepmedi recognized for pioneering efforts leveraging data and health technologies to advance potentially life-saving ideas aimed at improving patient care during the COVID-19 pandemic and beyond.
-
Johnson & Johnson to Address Racial and Social Injustice Through Platform that Aims to Eliminate Health Inequities for People of Color
11/17/2020
Johnson & Johnson commits $100 million over the next five years to invest in and promote health equity solutions
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
-
Johnson & Johnson secured more than $1 billion in additional funding for its COVID-19 vaccine research through an expansion of its partnership with the Biomedical Advanced Research and Development Authority.
-
Johnson & Johnson and U.S. Department of Health & Human Services Expand Agreement to Support Next Phase of COVID-19 Vaccine Candidate Research and Development
11/14/2020
Johnson & Johnson announced the expansion to the partnership between its Janssen Pharmaceutical Companies and the Biomedical Advanced Research and Development Authority, which is part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services for the ongoing development of Janssen's investigational COVID-19 vaccine candidate.
-
There was a handful of positive clinical trial news reported today. Here’s a look.
-
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2020
10/22/2020
Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2020 of $1.01 per share on the company's common stock.
-
The study is evaluating daratumumab monotherapy as maintenance treatment compared to observation, in other words, no treatment, for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.